Dr. Mahaffey is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000Fax+1 650-498-5840
Education & Training
- Duke University HospitalFellowship, Cardiovascular Disease, 1993 - 1996
- University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 1989 - 1993
- University of Washington School of MedicineClass of 1989
Certifications & Licensure
- CA State Medical License 2014 - 2026
- NC State Medical License 1996 - 2022
- AZ State Medical License 1993 - 1994
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Publications & Presentations
PubMed
- 1 citationsNatriuretic Peptides and Prognosis in Patients With Type 2 Diabetes Mellitus and High Risk for Cardiovascular Events.Muhammad Shahzeb Khan, James L Januzzi Jr, Yuxi Liu, Jialin Xu, Wayne Shaw
Journal of Cardiac Failure. 2024-04-16 - 50 citationsEffects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.James L. Januzzi, Jialin Xu, Jingwei Li, Wayne Shaw, Richard Oh
Journal of the American College of Cardiology. 2020-11-03 - 3226 citationsCanagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyVlado Perkovic, Meg Jardine, Bruce Neal, Severine Bompoint, Hiddo J.L. Heerspink
The New England Journal of Medicine. 2019-04-14
Journal Articles
- Alirocumab and Cardiovascular Outcomes After Acute Coronary SyndromeVera A Bittner, Kenneth W Mahaffey, Deepak L Bhatt, Robert A Harrington, Gregory G Schwartz, Matthew T Roe, The New England Journal of Medicine
- Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical RevascularizationKenneth Mahaffey, Manesh R Patel, W Schuyler Jones, William R Hiatt, Jeffrey S Berger, ScienceDirect
- Impact of Lesion Complexity on Peri-Procedural Adverse Events and the Benefit of Potent Intravenous Platelet Adenosine Diphosphate Receptor Inhibition After Percutaneo...Gregg W Stone, Matthew J Price, Philippe Genereux, C Michael Gibson, Deepak L Bhatt, Robert A Harrington, Kenneth W Mahaffey, European Heart Journal
- Join now to see all
Lectures
- Shark Tank Judge2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
- Effects of Canagliflozin on Heart Failure Outcomes With and Without Preserved Ejection Fraction in Type 2 Diabetes: Results From the CANVAS Program2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
- ROCKET-AF: Rivaroxaban Prevents Stroke as Effectively as Warfarin, With Lower Bleeding RiskAmerican Heart Association, Scientific Sessions 2010, Chicago, Illinois, USA
- Join now to see all
Authored Content
- 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsMarch 2017
Press Mentions
- Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMINovember 10th, 2022
- Chinese Herbal Medicine May Offer Benefits in STEMI: CTS-AMINovember 7th, 2022
- How Sweet We Need ItMay 30th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: